Why the study?
Rapid therapeutic development is required to improve HF management, and the potential of targeting beta-3 adrenoceptors in heart disease needs evaluation.
Design
Review
Key result
Beta-3 adrenoceptor stimulation mediates cardioprotective effects in heart failure, but its therapeutic role must be clarified through future clinical trials.
Authors
Loading...
Beta-3 adrenoceptor agonists merit heart failure trial evaluation; leaves open clinical utility pending randomized confirmation.
Beta-3 adrenoceptors represent a promising therapeutic target for heart failure due to their resistance to desensitization and cardioprotective signaling pathways.
Kayki‐Mutlu et al. (2019) conducted a review in Heart failure. Beta-3 adrenoceptor targeted therapy was evaluated. Beta-3 adrenoceptor stimulation mediates cardioprotective effects in heart failure, but its therapeutic role must be clarified through future clinical trials.